WHO pre-qualifies pneumococcal vaccine after study by MRC Unit The Gambia

The World Health Organization (WHO) has pre-qualified Pfizer’s PCV13 pneumococcal vaccine for global use, based on a trial conducted by the MRC Unit The Gambia.

In 2008, the WHO estimated that 541,000 children under five years old died from pneumococcal disease worldwide; Africa accounted for 57% of these deaths. Worryingly, antibiotic resistance to pneumococcal infections is also increasing, highlighting the importance of safe and effective vaccine strategies.

A new vaccine called PCV13 developed by Pfizer in collaboration with Gavi, the Vaccine Alliance, provided new hope for treatment.

About the project

In 2016, the MRC Unit The Gambia conducted a vaccine impact trial of PCV13 working with the Ministry of Health and Social Welfare of The Gambia. The study on 14,650 patients showed that using PCV13 in the Gambian Expanded Programme on Immunisation reduced severe pneumococcal pneumonia, sepsis, and meningitis in children by 55%.

A recent analysis in 2017 showed that the use of pneumococcal conjugate vaccine (PCV) in The Gambia reduced x-ray proven pneumonia in children by 24%, pneumococcal pneumonia by 63%, and very severe pneumonia by 61%. The study, which enrolled 18,833 participants, also shows the real-life impact of introducing PCV in a developing country.

Impacts of the project

In October 2016 the WHO pre-qualified PCV13, based on the MRC Unit The Gambia trial results. The pre-qualification allows the vaccine to be used globally by United Nations agencies, and by countries that require WHO pre-qualification.

The vaccine was introduced under the Advance Market Commitment programme, for shipment to countries supported by Gavi, the Vaccine Alliance. The expanded availability will enable Gavi-graduated countries to access the same pricing until 2025.

Professor Beate Kampmann, Trial Director and Theme Leader for Vaccines and Immunity at the MRC Unit The Gambia, said:

The MRC Unit The Gambia generated the key data for both licensure and WHO pre-qualification, and we are delighted to see this product come to market so speedily, as it will influence the availability of the pneumococcal vaccines in resource-poor settings.

In 2020 a modelling analysis estimated that the PCV13 vaccine has prevented over 175,000,000 cases of the disease and 624,000 deaths over the last decade.

PCV13 also provides significant logistical and economic benefits, including:

  • 75% reduction in temperature-controlled supply chain requirements
  • reduced shipping costs for the United Nations International Children’s Education Fund (UNICEF) shipping costs
  • reduced storage requirements at the national, regional, district, and community levels.

Find out more

Read about the vaccine study on Gateway to Research.

Read more about the 10 year public health impact of the PCV13 vaccine (Science Direct).

Visit the MRC Unit The Gambia website.

Top image:  Vaccination. Credit: Getty Images.

This is the integrated website of the seven research councils, Research England and Innovate UK.
Let us know if you have feedback or would like to help us test new developments.